Literature DB >> 10722607

Linkage of exogenous T-cell epitopes to the 19-kilodalton region of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP1(19).

N Ahlborg1, I T Ling, A A Holder, E M Riley.   

Abstract

The degree of protection against Plasmodium yoelii asexual blood stages induced by immunization of mice with the 19-kDa region of merozoite surface protein 1 (MSP1(19)) is H-2 dependent. As a strategy to improve the protection, mouse strains with disparate H-2 haplotypes were immunized with glutathione S-transferase (GST)-MSP1(19) proteins including either a universal T-cell epitope from tetanus toxin (P2) or an I-A(k)-restricted T-cell epitope (P8) from Plasmodium falciparum Pf332. In H-2(k) mice which are poorly protected following immunization with GST-MSP1(19), GST-P2-MSP1(19) significantly improved the protection. In mice partially (H-2(k/b)) or well protected by GST-MSP1(19) (H-2(d) and H-2(b)), P2 did not further increase the protection. However, the protection of H-2(k/b) mice and to some extent H-2(k) mice was improved by immunization with GST-P8-MSP1(19). The magnitudes of immunoglobulin G1 (IgG1) and IgG2a responses in mice immunized with the GST-MSP1(19) variants correlated with low peak parasitemia, indicating a protective capacity of these IgG subclasses. In H-2(k) mice immunized with GST-P2-MSP1(19), both IgG1 and IgG2a responses were significantly enhanced. The epitope P2 appeared to have a general ability to modulate the IgG subclass response since all four mouse strains displayed elevated IgG2a and/or IgG2b levels after immunization with GST-P2-MSP1(19). In contrast, GST-P8-MSP1(19) induced a slight enhancement of IgG responses in H-2(k/b) and H-2(k) mice without any major shift in IgG subclass patterns. The ability to improve the protective immunity elicited by P. yoelii MSP1(19) may have implications for improvement of human vaccines based on P. falciparum MSP1(19).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722607      PMCID: PMC97391          DOI: 10.1128/IAI.68.4.2102-2109.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  64 in total

1.  Generation of antibodies to human IL-12 and amphiregulin by immunization of Balb/c mice with diepitope multiple antigen peptides.

Authors:  N Ahlborg; S Paulie; S Braesch-Andersen
Journal:  J Immunol Methods       Date:  1997-05-12       Impact factor: 2.303

2.  Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum.

Authors:  K Tanabe; M Mackay; M Goman; J G Scaife
Journal:  J Mol Biol       Date:  1987-05-20       Impact factor: 5.469

3.  Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells.

Authors:  P Panina-Bordignon; A Tan; A Termijtelen; S Demotz; G Corradin; A Lanzavecchia
Journal:  Eur J Immunol       Date:  1989-12       Impact factor: 5.532

4.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  D B Smith; K S Johnson
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

Review 5.  Lymphokine control of in vivo immunoglobulin isotype selection.

Authors:  F D Finkelman; J Holmes; I M Katona; J F Urban; M P Beckmann; L S Park; K A Schooley; R L Coffman; T R Mosmann; W E Paul
Journal:  Annu Rev Immunol       Date:  1990       Impact factor: 28.527

6.  Characterization of immune responses to experimental polyvalent subunit vaccines assembled in iscoms.

Authors:  A Sjölander; N Ahlborg; S Ståhl; R Andersson
Journal:  Mol Immunol       Date:  1998-02       Impact factor: 4.407

7.  Plasmodium knowlesi: secondary processing of the malaria merozoite surface protein-1.

Authors:  M J Blackman; E D Dennis; E M Hirst; C H Kocken; T J Scott-Finnigan; A W Thomas
Journal:  Exp Parasitol       Date:  1996-07       Impact factor: 2.011

8.  Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains.

Authors:  M J Blackman; I T Ling; S C Nicholls; A A Holder
Journal:  Mol Biochem Parasitol       Date:  1991-11       Impact factor: 1.759

9.  The combined epidermal growth factor-like modules of Plasmodium yoelii Merozoite Surface Protein-1 are required for a protective immune response to the parasite.

Authors:  I T Ling; S A Ogun; A A Holder
Journal:  Parasite Immunol       Date:  1995-08       Impact factor: 2.280

10.  Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein.

Authors:  M J Blackman; T J Scott-Finnigan; S Shai; A A Holder
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

View more
  26 in total

1.  In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system.

Authors:  Alan L Y Pang; Caryn N Hashimoto; Leslie Q Tam; Z Q Meng; George S N Hui; Walter K K Ho
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

2.  Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.

Authors:  Hong Zhang; Hu Fu; Robert J Luallen; Bingfen Liu; Fang-Hua Lee; Robert W Doms; Yu Geng
Journal:  Vaccine       Date:  2015-08-13       Impact factor: 3.641

3.  Genetic immunization of BALB/c mice with a plasmid bearing the gene coding for a hybrid merozoite surface protein 1-hepatitis B virus surface protein fusion protects mice against lethal Plasmodium chabaudi chabaudi PC1 infection.

Authors:  G Wunderlich; I C Moura; H A del Portillo
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

4.  Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.

Authors:  Puneet K Gupta; Paushali Mukherjee; Shikha Dhawan; Alok K Pandey; Suman Mazumdar; Deepak Gaur; S K Jain; Virander S Chauhan
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

5.  Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum.

Authors:  Asma Abdullah Nurul; Mohd Nor Norazmi
Journal:  Parasitol Res       Date:  2010-11-06       Impact factor: 2.289

6.  MHC heterozygosity confers a selective advantage against multiple-strain infections.

Authors:  Dustin J Penn; Kristy Damjanovich; Wayne K Potts
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

7.  Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli.

Authors:  Suraksha Sachdeva; Gul Ahmad; Pawan Malhotra; Paushali Mukherjee; V S Chauhan
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  Immune responses of mice with different genetic backgrounds to improved multiepitope, multitarget malaria vaccine candidate antigen FALVAC-1A.

Authors:  S A Kaba; A Price; Z Zhou; V Sundaram; P Schnake; I F Goldman; A A Lal; V Udhayakumar; C W Todd
Journal:  Clin Vaccine Immunol       Date:  2008-09-10

9.  Analysis of immunological nonresponsiveness to the 19-kilodalton fragment of merozoite surface Protein 1 of Plasmodium yoelii: rescue by chemical conjugation to diphtheria toxoid (DT) and enhancement of immunogenicity by prior DT vaccination.

Authors:  Danielle I Stanisic; Laura B Martin; Xue Q Liu; David Jackson; Juan Cooper; Michael F Good
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

10.  Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.

Authors:  Balwan Singh; Monica Cabrera-Mora; Jianlin Jiang; Mary Galinski; Alberto Moreno
Journal:  Vaccine       Date:  2010-01-22       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.